Clinical outcomes are complex and often involve multiple systems. Early identification and standardization of clinical trials are essential for improving prognosis. Diagnosis of this disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological reactivity.
Platforms can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of self-immunized treatment programs require individual development, usually including drug therapy, rehabilitation prevention, and regular follow-up management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adaptation to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of HL with autoimmune diseases. The platform serves China International Medical Service System, a team of nationally and internationally authoritative experts in the field of blood tumours, who provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.